SBC113

SBC113 is a preclinical-stage small molecule being developed by SapiensBio for the treatment of various fibrotic diseases. Discovered using the company's proprietary SAPIENTIA platform, which utilizes data-driven AI and machine learning for drug discovery, SBC113 is designed to modulate a novel molecular target involved in the pathogenesis of fibrosis. As of early 2024, the program is in the lead optimization phase, with efforts focused on refining lead compounds into clinical candidate grade. While the specific molecular target remains undisclosed, the drug is part of a pipeline aimed at addressing high unmet needs in fibrosis through the identification of novel biological pathways.